Overview

A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD

Status:
RECRUITING
Trial end date:
2027-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in pediatric ADHD patients.
Phase:
PHASE2
Details
Lead Sponsor:
Otsuka Pharmaceutical Co., Ltd.
Treatments:
1-(naphthalen-2-yl)-3-azabicyclo(3.1.0)hexane